[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Celcuity Inc (CELC)

Celcuity Inc (CELC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,357,883
  • Shares Outstanding, K 48,932
  • Annual Sales, $ 0 K
  • Annual Income, $ -177,040 K
  • EBIT $ -209 M
  • EBITDA $ -205 M
  • 60-Month Beta 0.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 53.74% (-2.99%)
  • Historical Volatility 50.65%
  • IV Percentile 1%
  • IV Rank 26.62%
  • IV High 142.03% on 10/17/25
  • IV Low 21.71% on 08/26/26
  • Expected Move (DTE 17) 8.46 (9.19%)
  • Put/Call Vol Ratio 0.19
  • Today's Volume 1,551
  • Volume Avg (30-Day) 731
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 22,677
  • Open Int (30-Day) 25,861
  • Expected Range 83.52 to 100.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.50
  • Number of Estimates 3
  • High Estimate $-1.24
  • Low Estimate $-1.75
  • Prior Year $-0.92
  • Growth Rate Est. (year over year) -63.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
83.04 +10.77%
on 08/14/26
96.16 -4.35%
on 08/26/26
+5.60 (+6.48%)
since 07/31/26
3-Month
78.60 +17.02%
on 07/28/26
117.21 -21.53%
on 07/07/26
-30.98 (-25.20%)
since 06/01/26
52-Week
44.42 +107.07%
on 10/02/25
151.02 -39.09%
on 05/04/26
+40.75 (+79.54%)
since 08/29/25

Most Recent Stories

More News
Celcuity To Participate in Upcoming Investor Conferences

MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid...

CELC : 91.98 (+3.28%)
Celcuity To Participate in Upcoming Investor Conferences

MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid...

CELC : 91.98 (+3.28%)
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications,...

CELC : 91.98 (+3.28%)
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

If approved, REVTORPYK would be the first and only therapy for advanced breast cancer with a PIK3CA mutation that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2...

CELC : 91.98 (+3.28%)
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update

REVTORPYK™ (gedatolisib) approved by the U.S. FDA for the treatment of HR+/HER2- PIK3CA Wild-Type locally advanced or metastatic breast cancer on July 14, 2026; on track for commercial launch late third...

CELC : 91.98 (+3.28%)
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update

MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor...

CELC : 91.98 (+3.28%)
Can Celcuity Still Lose Less Than Expected When Expectations Are Already Rock Bottom?

Barchart Research What to Expect from CELC Earnings CELC Generated August 12, 2026 Current Price $92.08 EPS Estimate $$-1.08 Consensus Rating Strong Buy Average Move 4.12% Can Celcuity Still Lose Less...

CELC : 91.98 (+3.28%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC

NEW YORK , Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Celcuity Inc. ("Celcuity" or the "Company") (NASDAQ: CELC).  Such investors are advised to...

CELC : 91.98 (+3.28%)
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call

 MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and...

CELC : 91.98 (+3.28%)
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call

 MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment...

CELC : 91.98 (+3.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's...

See More

Key Turning Points

3rd Resistance Point 97.88
2nd Resistance Point 95.36
1st Resistance Point 93.67
Last Price 91.98
1st Support Level 89.47
2nd Support Level 86.95
3rd Support Level 85.26

See More

52-Week High 151.02
Fibonacci 61.8% 110.30
Fibonacci 50% 97.72
Last Price 91.98
Fibonacci 38.2% 85.14
52-Week Low 44.42

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.